Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study.


Baskin E., Fidan K., GÜLHAN B., Gulleroglu K., CANPOLAT N., Yilmaz A., ...Daha Fazla

Journal of nephrology, cilt.35, sa.4, ss.1213-1222, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1007/s40620-021-01212-w
  • Dergi Adı: Journal of nephrology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.1213-1222
  • Anahtar Kelimeler: Eculizumab treatment, Pediatric patient, Atypical hemolytic uremic syndrome, Eculizumab discontinuation
  • Gazi Üniversitesi Adresli: Evet

Özet

Introduction Eculizumab is effective treatment of pediatric atypical hemolytic uremic syndrome (aHUS). However, the optimal duration of treatment is not clearly defined. The aim of this study was to retrospectively analyze the outcome of pediatric patients with aHUS, who started eculizumab treatment but discontinued it during the follow-up period.